Concepedia

Hanne Lind

HL

Statistics

Publications

6

Citations

430

H-Index

6

Active since

2015

Affiliations

University of Colorado Anschutz Medical Campus(Current)

Syntrix Biosystems (United States)

National Cancer Institute

Hanne Lind is an author at University of Colorado Anschutz Medical Campus specializing in medicine, oncology, and signal transduction in cancer.

Publications per year

2015–2024

6

Publications

6

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i>

Valerie N. Barton, Nicholas C. D’Amato, Melita A. Gordon et al. · Molecular Cancer Therapeutics · 2015 · 242 citations · Full text

Medicine, Oncology, Pharmacology +17

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

Lucas A. Horn, Jeffrey Riskin, Heidi Hempel et al. · Journal for ImmunoTherapy of Cancer · 2020 · 96 citations · Full text

Medicine, Cancer Biology, Oncology +17

Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells

Alexandra Thomas, Hanne Lind, Angela Hong et al. · Cell Cycle · 2017 · 51 citations · Full text

Medicine, Cancer Biology, Oncology +16

NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer

Kathleen O’Neill, Li‐Wei Kuo, Michelle M. Williams et al. · Cancers · 2022 · 20 citations · Full text

Medicine, Molecular Biology, Oncology +15

MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1/anti-TGF-β in squamous cell carcinomas with enhanced CD8 T cell memory-driven response

Hanne Lind, Spencer C. Hall, Alexander A. Strait et al. · Cancer Letters · 2024 · 11 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 6